Cargando…

The clinical application of linagliptin in Asians

Asia has a growing diabetic population. Linagliptin, a member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics of rapid attainment of steady state, little accumulation, predominantly nonrenal route of elimination, prolonged terminal half...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Chu-qing, Xiang, Yu-fei, Zhou, Zhi-guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577268/ https://www.ncbi.nlm.nih.gov/pubmed/26396526 http://dx.doi.org/10.2147/TCRM.S64402

Ejemplares similares

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials
por: Ning, Guang, et al.
Publicado: (2017)

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
por: Ma, Ronald CW, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
por: Haak, Thomas
Publicado: (2015)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Linagliptin: A thorough Characterization beyond Its Clinical Efficacy
por: Sortino, Maria Angela, et al.
Publicado: (2013)

Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy
por: Liu, Jie, et al.
Publicado: (2022)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes
por: Sarashina, Akiko, et al.
Publicado: (2016)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
por: Woo, V.
Publicado: (2015)

Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020)

Atypical Bullous Pemphigoid After Linagliptin Intake
por: Dbouk, Samer, et al.
Publicado: (2021)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
por: Aroor, Annayya R., et al.
Publicado: (2018)

DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
por: Hasegawa, Yu, et al.
Publicado: (2017)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
por: Gallwitz, Baptist
Publicado: (2015)

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark, Lene, et al.
Publicado: (2012)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
por: Nagai, Takuo, et al.
Publicado: (2016)

Post-marketing Study of Linagliptin: A Pilot Study
por: Gomes, Gabrielle Kéfrem Alves, et al.
Publicado: (2019)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Spectrophotometric Methods for the Determination of Linagliptin in Binary Mixture with Metformin Hydrochloride and Simultaneous Determination of Linagliptin and Metformin Hydrochloride using High Performance Liquid Chromatography
por: El-Bagary, Ramzia I., et al.
Publicado: (2013)

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
por: Keshavarz, Khosro, et al.
Publicado: (2017)

Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin
por: Huang, Yiwen, et al.
Publicado: (2016)

Linagliptin Inhibits Lipopolysaccharide-Induced Inflammation Concentration-Dependently And -Independently
por: Sato, Naoki, et al.
Publicado: (2019)

Linagliptin/metformin/pembrolizumab interaction: Various toxicities: case report
Publicado: (2022)

Mild Pancreatitis Induced by Linagliptin Revealed by a Medication Review
por: Gidda, Harish, et al.
Publicado: (2023)

Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases
por: Wiciński, Michał, et al.
Publicado: (2019)

The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial
por: Karimifar, Mozhgan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_019bf58i3ao3v3ah7209a7atcg